Serina Therapeutics, Inc.
SERHealthcare|Biotechnology|US
$1.38
-0.27 (-16.36%)
DCF Value
$0.10
Tangible Book / Share
$1.14
Cash / Share
$1.41
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07422675 SAD Study in Patients With Parkinson's Disease and Motor Fluctuations | PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease | P1 | Recruiting | 40 | RCT, Double-blind | SER-252 (PEOZ-apomorphine) |
| NCT02579473 A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 | Parkinson's Disease | P1 | Unknown | 20 | Open-label | SER-214 |